Limits...
Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.

Kaku Y, Nagaya H, Tsuchiya A, Kanno T, Gotoh A, Tanaka A, Shimizu T, Nakao S, Tabata C, Nakano T, Nishizaki T - Cancer Sci. (2014)

Bottom Line: The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM.HUHS1015 induced both necrosis and apoptosis of MSTO-211H and NCI-H2052 cells.HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis.

View Article: PubMed Central - PubMed

Affiliation: Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan.

Show MeSH

Related in: MedlinePlus

Effect of HUHS1015 on malignant pleural mesothelioma cell viability. MSTO-211H (a), NCI-H28 (b), NCI-H2052 (c), and NCI-H2452 cells (d) were treated with HUHS1015, paclitaxel, or cisplatin at concentrations as indicated for 24 h, and cell viability was quantified with an MTT assay. Data represent the mean (±SEM) percentage of basal levels (MTT intensities of untreated cells) (n = 4 independent experiments).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317914&req=5

fig02: Effect of HUHS1015 on malignant pleural mesothelioma cell viability. MSTO-211H (a), NCI-H28 (b), NCI-H2052 (c), and NCI-H2452 cells (d) were treated with HUHS1015, paclitaxel, or cisplatin at concentrations as indicated for 24 h, and cell viability was quantified with an MTT assay. Data represent the mean (±SEM) percentage of basal levels (MTT intensities of untreated cells) (n = 4 independent experiments).

Mentions: HUHS1015 reduced the cell viability of all the investigated malignant pleural mesothelioma cell lines, MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, in a concentration (1–100 μM)-dependent manner; a drastic effect was found at concentrations more than 30 μM, with the viability reaching almost 0% of basal levels at 100 μM (Fig. 2). The anticancer drug paclitaxel apparently reduced cell viability of all the investigated malignant pleural mesothelioma cell lines at concentrations higher than 1 μM, reaching 40–50% of basal levels at 100 μM (Fig. 2). Another anticancer drug, cisplatin, reduced the viability of malignant pleural mesothelioma cells by a much lesser extent than paclitaxel (Fig. 2). Collectively, these results suggest that HUHS1015 induces malignant pleural mesothelioma cell death effectively at concentrations higher than 30 μM.


Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.

Kaku Y, Nagaya H, Tsuchiya A, Kanno T, Gotoh A, Tanaka A, Shimizu T, Nakao S, Tabata C, Nakano T, Nishizaki T - Cancer Sci. (2014)

Effect of HUHS1015 on malignant pleural mesothelioma cell viability. MSTO-211H (a), NCI-H28 (b), NCI-H2052 (c), and NCI-H2452 cells (d) were treated with HUHS1015, paclitaxel, or cisplatin at concentrations as indicated for 24 h, and cell viability was quantified with an MTT assay. Data represent the mean (±SEM) percentage of basal levels (MTT intensities of untreated cells) (n = 4 independent experiments).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317914&req=5

fig02: Effect of HUHS1015 on malignant pleural mesothelioma cell viability. MSTO-211H (a), NCI-H28 (b), NCI-H2052 (c), and NCI-H2452 cells (d) were treated with HUHS1015, paclitaxel, or cisplatin at concentrations as indicated for 24 h, and cell viability was quantified with an MTT assay. Data represent the mean (±SEM) percentage of basal levels (MTT intensities of untreated cells) (n = 4 independent experiments).
Mentions: HUHS1015 reduced the cell viability of all the investigated malignant pleural mesothelioma cell lines, MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, in a concentration (1–100 μM)-dependent manner; a drastic effect was found at concentrations more than 30 μM, with the viability reaching almost 0% of basal levels at 100 μM (Fig. 2). The anticancer drug paclitaxel apparently reduced cell viability of all the investigated malignant pleural mesothelioma cell lines at concentrations higher than 1 μM, reaching 40–50% of basal levels at 100 μM (Fig. 2). Another anticancer drug, cisplatin, reduced the viability of malignant pleural mesothelioma cells by a much lesser extent than paclitaxel (Fig. 2). Collectively, these results suggest that HUHS1015 induces malignant pleural mesothelioma cell death effectively at concentrations higher than 30 μM.

Bottom Line: The newly synthesized naftopidil analogue HUHS1015 reduced cell viability in malignant pleural mesothelioma cell lines MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452, with the potential greater than that for the anticancer drugs paclitaxel or cisplatin at concentrations higher than 30 μM.HUHS1015 induced both necrosis and apoptosis of MSTO-211H and NCI-H2052 cells.HUHS1015 upregulated expression of mRNAs for Puma, Hrk, and Noxa in MSTO-211H and NCI-H2052 cells, suggesting HUHS1015-induced mitochondrial apoptosis.

View Article: PubMed Central - PubMed

Affiliation: Division of Bioinformation, Department of Physiology, Hyogo College of Medicine, Nishinomiya, Japan.

Show MeSH
Related in: MedlinePlus